Since obesity, HFpEF, and atrial fibrillation are interrelated, novel pharmacotherapies such as glucagon-like peptide 1 (GLP-1) receptor agonist might be proven a valuable addition in the therapeutic armamentarium for AF management. Here, GCG is linked to obesity disorder.